Baicalin As A Treatment For Sars Infection
- Summary
- The Present Invention Relates To A Pharmaceutical Composition Useful For The Treatment Of Diseases Associated With Viruses Of The Order Nidovirales Of The Family Coronaviradae, Such As Severe Acute Respiratory Syndrome (Sars) Viruses In Humans And Other Animals. In Particular, This Invention Relates To A Naturally Occurring Compound, Namely, Baicalin, Extracted And Purified From The Chinese Medicinal Plant Scutellaria Baicalensis Georgi (Chinese Name: Huang Qin), That Exhibits Potent Antiviral Activity Against Members Of The Order Nidovirales Of The Family Coronaviradae That Infects Humans And Other Animals; In Particular, Sars Viruses In Humans ("Hsars Virus").; The Invention Also Relates To A Therapeutic Method, Using Pharmaceutical Compositions Comprising Baicalin Compounds, For The Treatment, Amelioration, Management Or Prevention Of Diseases Associated With Members Of The Order Nidovirales Of The Family Coronaviradae, Such As Hsars.
- Supplementary Information
- Patent Number: US7605135B2
Application Number: US2004983985A
Inventor: Yuen, Kwok Yung | Chen, Feng | Chan, Kwok Hung | Kao, Yi Tsun | Guan, Yi | Poon, Leo Lit Man | Peiris, JSM
Priority Date: 10 Nov 2003
Priority Number: US7605135B2
Application Date: 8 Nov 2004
Publication Date: 20 Oct 2009
IPC Current: A01N004304 | A61K0031382 | A61K00317048
US Class: 514033
Assignee Applicant: The University of Hong Kong
Title: Baicalin as a treatment for SARS infection
Usefulness: Baicalin as a treatment for SARS infection
Summary: (A) is useful for the treatment of diseases associated with a virus (human severe acute respiratory syndrome (hSARS) virus) that belongs to the order nidovirales of the family coronaviridae in human (claimed).
Novelty: Composition, useful for the treatment of diseases associated with virus that belongs to the order nidovirales of the family Coronaviridae, comprises baicalin compounds
- Industry
- Biomedical
- Sub Category
- Pathogen
- Application No.
- US2004983985A
- Country/Region
- Hong Kong
For more information, please click Here
